ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,505.00
-0.71%
US Tech 100
19,132.00
0.64%
Dow Jones
40,287.53
-0.93%
Brent Oil
81.98
-0.36%
Bitcoin
67,052.91
-1.62%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Spyre Therapeutics Inc (SYRE)

  7. Spyre Therapeutics Inc (SYRE) News

SYRE

Spyre Therapeutics (SYRE)

Spyre Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SYRE
DateTimeSourceHeadlineSymbolCompany
07/18/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of DirectorsNASDAQ:SYRESpyre Therapeutics Inc
06/18/20247:30AMPR Newswire (US)Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel DiseaseNASDAQ:SYRESpyre Therapeutics Inc
06/03/20245:23PMPR Newswire (US)Spyre Therapeutics Announces Grants of Inducement AwardsNASDAQ:SYRESpyre Therapeutics Inc
05/30/20244:33PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SYRESpyre Therapeutics Inc
05/29/20248:30AMPR Newswire (US)Spyre Therapeutics to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:SYRESpyre Therapeutics Inc
05/16/20244:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRESpyre Therapeutics Inc
05/16/20244:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRESpyre Therapeutics Inc
05/16/20244:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRESpyre Therapeutics Inc
05/16/20244:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRESpyre Therapeutics Inc
05/16/20244:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRESpyre Therapeutics Inc
05/16/20244:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRESpyre Therapeutics Inc
05/16/20244:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRESpyre Therapeutics Inc
05/16/20244:05PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SYRESpyre Therapeutics Inc
05/15/20247:40AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SYRESpyre Therapeutics Inc
05/15/20247:30AMPR Newswire (US)Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of DirectorsNASDAQ:SYRESpyre Therapeutics Inc
05/09/20244:11PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SYRESpyre Therapeutics Inc
05/09/20244:08PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SYRESpyre Therapeutics Inc
05/09/20244:02PMPR Newswire (US)Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:SYRESpyre Therapeutics Inc
05/03/20245:00PMPR Newswire (US)Spyre Therapeutics Announces Grants of Inducement AwardsNASDAQ:SYRESpyre Therapeutics Inc
04/01/20245:00PMPR Newswire (US)Spyre Therapeutics Announces Grants of Inducement AwardsNASDAQ:SYRESpyre Therapeutics Inc
03/18/20248:00AMPR Newswire (US)Spyre Therapeutics Announces $180 Million Private PlacementNASDAQ:SYRESpyre Therapeutics Inc
03/05/20245:15PMEdgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:SYRESpyre Therapeutics Inc
03/01/20245:25PMPR Newswire (US)Spyre Therapeutics Announces Grants of Inducement AwardsNASDAQ:SYRESpyre Therapeutics Inc
03/01/20246:14AMEdgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:SYRESpyre Therapeutics Inc
02/29/20245:06PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SYRESpyre Therapeutics Inc
02/29/20244:14PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SYRESpyre Therapeutics Inc
02/29/20244:05PMPR Newswire (US)Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:SYRESpyre Therapeutics Inc
02/26/20247:30AMPR Newswire (US)Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care ConferenceNASDAQ:SYRESpyre Therapeutics Inc
02/20/20249:21PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRESpyre Therapeutics Inc
02/14/20248:47PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SYRESpyre Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SYRE

Your Recent History

LSE
PV68
Anz Bank 27
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved